When it comes to vaccinating the world, the simpler the dosing regimen the better. That’s why public-health officials welcomed Johnson & Johnson–Janssen Pharmaceuticals’ one-dose COVID-19 vaccine. The shot is 66% efficacious overall in protecting people from COVID-19 disease, and even more so in preventing the worst outcomes. After concerns were raised over rare blood-clotting side effects, U.S. health officials paused use of the shot in early April but resumed vaccination—with the potential clotting risk listed among the side effects—after determining the benefits outweigh the risks.
- Inside Mississippi's Last Abortion Clinic—and the Biggest Fight for Abortion Rights in a Generation
- Do Current COVID-19 Tests Still Detect Omicron?
- The First U.S. Offshore Wind Farm Could Be a Lifeline for Struggling New England Cities
- Welcome to TV's Era of Peak Redundancy
- The Key Role a Local Newspaper Played in the Trial Over Ahmaud Arbery's Murder
- TIME's Top 100 Photos of 2021
- 2021: The Year the Grift Kept Giving